Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F12 | P00748 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892090 | 0.80 | ADORA3 (0.57) | ADORA3CCNE1CDK2CDK3CNR2 | |
| SCHEMBL9891969 | 0.76 | CCNE1 (0.52) | CCNE1CDK2CDK3CNR2PORCN | |
| SCHEMBL13284774 | 0.73 | CCNE1 (0.51) | CCNE1CDK2CDK3CNR2PORCN | |
| SCHEMBL9106117 | 0.71 | CNR2 (0.52) | CCNE1CDK2CDK3CNR2PORCN | |
| SCHEMBL9891937 | 0.71 | SMN1; SMN2 (0.60) | CCNE1CDK2CDK3CNR2CNR1 | |
| SCHEMBL15665095 | 0.71 | POLB (0.60) | CYP2C9CYP2C19F2 | |
| SCHEMBL3708048 | 0.70 | FFAR1 (0.53) | CCNE1CDK2CDK3CNR2CNR1 | |
| SCHEMBL1274844 | 0.70 | FFAR1 (0.53) | CCNE1CDK2CDK3CNR2CNR1 | |
| SCHEMBL9104214 | 0.70 | FFAR1 (0.53) | CCNE1CDK2CDK3CNR2CNR1 | |
| SCHEMBL9891944 | 0.69 | CNR2 (0.56) | CCNE1CDK2CDK3CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ADORA3 215/4885ADORA2A 123/4885ADORA1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.